Treatment with peginterferon versus interferon in Chinese patients with chronic hepatitis C.
Higher sustained virological response (SVR) rates after treating with peginterferon than after treating with interferon have been obtained in some randomized clinical trials (RCTs) in Chinese patients with chronic hepatitis C (CHC). However, the numbers of patients included in these clinical trials were too small to draw a clear conclusion. Therefore, a new meta-analysis including a large number of patients was needed to compare peginterferon with interferon in the treatment of Chinese CHC patients. A search of Medline, the China National Knowledge Infrastructure, the Wanfang Database, and the China Biomedical Database for relevant articles published between 1966 and 2009 was performed. RCTs comparing the use of peginterferon and interferon for the treatment of Chinese patients with CHC were assessed. Of the 236 studies screened, 18 RCTs including 1,148 patients (659 treated with peginterferon therapy and 489 treated with interferon therapy) were analyzed. The total SVR rates obtained in patients treated with peginterferon were significantly higher than those obtained in patients treated with interferon (64% vs. 40%; relative risk, 1.56; 95% confidence interval: 1.28-1.91; p < 0.01), but the difference between the peginterferon α-2b and interferon α-2b treatments was not significant. Withdrawal rates were similar between patients treated with peginterferon and interferon. Chinese patients with CHC have a greater likelihood of achieving an SVR with peginterferon α-2a.
Zhao
S
S
Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University School of Medicine, Shaanxi, China. sihaizhao@mail.xjtu.edu.cn
Liu
E
E
Wei
K
K
Wang
Y
Y
Li
Y
Y
Huang
B
B
Chen
Y
Y
Yang
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002681:China; D005260:Female; D016174:Hepacivirus / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014766:Viremia / Q000188:drug therapy; D028761:Withholding Treatment / Q000706:statistics & numerical data; D055815:Young Adult
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b
Semin Liver Dis. 2003;23 Suppl 1:1-2
12934161
J Infect Dis. 2009 Apr 15;199(8):1112-20
19284286
J Hepatol. 1999 May;30(5):956-61
10365827
J Hepatol. 2002 Oct;37(4):500-6
12217604
Hepatology. 2001 Aug;34(2):395-403
11481625
Aliment Pharmacol Ther. 2004 Nov 1;20(9):931-8
15521839
Am J Med. 2005 Aug;118(8):808-15
16084169
N Engl J Med. 2004 Jul 29;351(5):438-50
15282351
Ann Intern Med. 2004 Mar 2;140(5):346-55
14996676
Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S
9305658
N Engl J Med. 2002 Sep 26;347(13):975-82
12324553
Int J Clin Pract. 2009 Sep;63(9):1334-9
19691617
Trends Biotechnol. 1995 Mar;13(3):86-91
7766222
Hepatology. 1999 Sep;30(3):787-93
10462387
Zhonghua Gan Zang Bing Za Zhi. 2007 Mar;15(3):231
17407724
Sidahora. 2002;(4):8-10
12703472
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2006 Jun;20(2):42-5
16816861
N Engl J Med. 2001 Jul 5;345(1):41-52
11439948
Lancet. 2001 Sep 22;358(9286):958-65
11583749
Antivir Chem Chemother. 2004 Nov;15(6):287-97
15646642
J Med Virol. 2001 Nov;65(3):510-6
11596086
Hepatology. 2003 Mar;37(3):590-9
12601357